

# **Dermayant is committed to** fostering unprecedented change and unparalleled impact in immuno-dermatology.

We're doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases.

# **Dermavant at-a-glance**

- Clinical-stage biopharmaceutical company
- Founded September 2015
- A subsidiary of Roivant Sciences
- U.S. operations in Long Beach, California and Raleigh-Durham, North Carolina

## **About Dermavant**

### A Passion for Science and a Commitment to Dermatology

Dermayant Sciences, a subsidiary of Roivant Sciences, is a clinicalstage bio-pharmaceutical company focused on developing products that represent new treatment categories and address some of the greatest challenges providers and patients encounter.

The company's robust medical dermatology pipeline includes both late-stage and early-development product candidates that target specific unmet needs in two of the largest growing immunedermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis, and acne.

Dermavant is developing its lead product candidate, tapinarof (DMVT-505), as a novel therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of plaque psoriasis and atopic dermatitis, which affect approximately 8 million and 27 million people in the United States, respectively.

# **Management team**

#### **Todd Zavodnick**

Chief Executive Officer

### Philip M. Brown, MD, JD

Chief Medical Officer

#### **Chris Chapman**

**Chief Commercial Officer** 

### David Rubenstein, MD, PhD

Chief Scientific Officer

#### Christopher Van Tuyl, JD


**General Counsel** 





# **Dermavant has five product candidates addressing:**

Psoriasis · Atopic Dermatitis · Vitiligo · Hyperhidrosis · Acne



**Excludes certain Asian territories** 

### Key U.S. market data as of 2019

### Psoriasis: 8M patients<sup>1</sup>

- \$12.0B sales<sup>2</sup>
- \$19.3B by 2026<sup>2</sup>
- Topical treatments are ~80% of U.S. Rxs<sup>3,4</sup>

#### Atopic dermatitis: 27M patients<sup>5</sup>

- \$1.8B sales<sup>2</sup>
- \$5.7B by 2026<sup>2</sup>
- Topical treatments are ~97% of U.S. Rxs<sup>3,4</sup>

#### Vitiligo: 2.4M patients<sup>6</sup>

• No FDA-approved therapies

#### Hyperhidrosis: 15.3M patients<sup>7</sup>

No FDA-approved systemic treatments

**References: 1.** National Psoriasis Foundation. **2.** Evaluate Pharma. **3.** IQVIA NDTI 2020. **4.** Symphony Prescriber Source 2020. **5.** National Eczema Association. **6.** Rose & Mackay, US Census. **7.** Doolittle, J. et al. Arch Dermatol Res, 2016, 308:743-749; US Census.

**Main Phone Number: 919-767-3277** 

Company locations: Long Beach, California Office Dermavant Sciences, Inc. 3780 Kilroy Airport Way, Suite 250 Long Beach, CA 90806

Raleigh-Durham, North Carolina Office Dermavant Sciences, Inc. 3300 Paramount Parkway, Suite 150 Morrisville, NC 27560 Basel, Switzerland Office Dermavant Sciences GmbH Viaduktstrasse 8 4051 Basel